BR0313480A - Derivados de purina - Google Patents
Derivados de purinaInfo
- Publication number
- BR0313480A BR0313480A BR0313480-6A BR0313480A BR0313480A BR 0313480 A BR0313480 A BR 0313480A BR 0313480 A BR0313480 A BR 0313480A BR 0313480 A BR0313480 A BR 0313480A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- disorders
- unbranched
- branched
- independently
- Prior art date
Links
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 title 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 231100000360 alopecia Toxicity 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000565 sulfonamide group Chemical group 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"DERIVADOS DE PURINA". A presente invenção refere-se a compostos de fórmula (I) ou a sais farmaceuticamente aceitáveis dos mesmos, em que um de R^ 1^ e R^ 2^ é metila, etila ou isopropila e o outro é H; R^ 3^ e R^ 4^ são cada um independentemente H, C~ 1~-C~ 6~ alquila ramificada ou não-ramificada ou arila e em que pelo menos um de R^ 3^ e R^ 4^ não é H; R^ 5^ é um grupo C~ 1~-C~ 5~ alquila ramificado ou não-ramificado ou um grupo C~ 1~-C~ 6~, cicloalquila, cada um dos quais pode ser opcionalmente substituído com um ou mais grupos OH; R^ 6^, R^ 7^, R^ 8^ e R^ 9^ são cada um independentemente H, halogênio, NO~ 2~, OH, OMe, CN, NH~ 2~, COOH, CONH~ 2~ OU SO~ 2~NH~ 2~. Um outro aspecto da invenção refere-se a composições farmacêuticas que compreendem compostos de fórmula (I) e ao uso dos ditos compostos no tratamento de distúrbios proliferativos, distúrbios virais, distúrbios do SNC, diabete, derrame, alopecia ou distúrbios neurodegenerativos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0219052.8A GB0219052D0 (en) | 2002-08-15 | 2002-08-15 | New puring derivatives |
| PCT/GB2003/003544 WO2004016613A2 (en) | 2002-08-15 | 2003-08-13 | Purine derivatives and their use as antiproliferative agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0313480A true BR0313480A (pt) | 2005-06-21 |
Family
ID=9942406
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0313480-6A BRPI0313480B1 (pt) | 2002-08-15 | 2003-08-13 | Purina derivatives, its preparation processes, pharmaceutical compositions understanding the same and uses of the above derived from the preparation of medicines |
| BR0313480-6A BR0313480A (pt) | 2002-08-15 | 2003-08-13 | Derivados de purina |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0313480-6A BRPI0313480B1 (pt) | 2002-08-15 | 2003-08-13 | Purina derivatives, its preparation processes, pharmaceutical compositions understanding the same and uses of the above derived from the preparation of medicines |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7544689B2 (pt) |
| EP (1) | EP1534708B1 (pt) |
| JP (1) | JP4787495B2 (pt) |
| CN (1) | CN1312152C (pt) |
| AT (1) | ATE324374T1 (pt) |
| AU (1) | AU2003251063B2 (pt) |
| BR (2) | BRPI0313480B1 (pt) |
| CA (1) | CA2488834C (pt) |
| DE (1) | DE60304871T2 (pt) |
| GB (2) | GB0219052D0 (pt) |
| IL (1) | IL166783A (pt) |
| MX (1) | MXPA05001842A (pt) |
| NZ (1) | NZ538136A (pt) |
| WO (1) | WO2004016613A2 (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2741881B1 (fr) * | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
| GB0012528D0 (en) * | 2000-05-23 | 2000-07-12 | Univ Palackeho | Triterpenoid derivatives |
| JP4381804B2 (ja) * | 2001-06-27 | 2009-12-09 | サイクラセル リミテッド | ２，６，９−置換プリン誘導体及び増殖性疾患の治療におけるその使用 |
| GB0219054D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New purine derivatives |
| GB0219052D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New puring derivatives |
| ES2403558T3 (es) * | 2004-08-27 | 2013-05-20 | Cyclacel Limited | Inhibidores purínicos y pirimidínicos de CDK y su uso para el tratamiento de enfermedades autoinmunitarias |
| GB0606283D0 (en) * | 2006-03-29 | 2006-05-10 | Cyclacel Ltd | Process |
| KR20090035662A (ko) | 2006-05-19 | 2009-04-10 | 토피겐 파마슈티컬스 인코포레이티드 | 포스포디에스테라아제의 발현에 영향을 미치는 올리고누클레오티드 |
| GB0706632D0 (en) | 2007-04-04 | 2007-05-16 | Cyclacel Ltd | New purine derivatives |
| CZ302122B6 (cs) * | 2009-01-28 | 2010-10-20 | Univerzita Palackého v Olomouci | Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující |
| WO2011071491A1 (en) * | 2009-12-09 | 2011-06-16 | Signal Pharmaceuticals, Llc | Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol |
| GB201001075D0 (en) | 2010-01-22 | 2010-03-10 | Cyclacel Ltd | Crystalline forms |
| US9498471B2 (en) | 2011-10-20 | 2016-11-22 | The Regents Of The University Of California | Use of CDK9 inhibitors to reduce cartilage degradation |
| JP6930913B2 (ja) | 2014-10-14 | 2021-09-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | 炎症を阻害するためのｃｄｋ９及びｂｒｄ４阻害剤の使用法 |
| CN118598874A (zh) * | 2024-05-21 | 2024-09-06 | 江南大学 | 一种取代的9h嘌呤类化合物、药物组合物及其用途 |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2164271A (en) * | 1937-08-13 | 1939-06-27 | Purdue Research Foundation | Secondary aminoalcohols |
| CH270828A (de) * | 1946-12-23 | 1950-09-30 | Limited Polymerisable Products | Verfahren zur Herstellung eines Aminoalkohols. |
| EP0457773A4 (en) | 1989-01-31 | 1993-03-10 | Whitby Research Incorporated | N?6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists |
| GB9204015D0 (en) | 1992-02-25 | 1992-04-08 | Wellcome Found | Therapeutic nucleosides |
| US5688774A (en) | 1993-07-13 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
| JP3396924B2 (ja) | 1993-09-07 | 2003-04-14 | 日本曹達株式会社 | 活性汚泥のバルキング防止剤 |
| DE69513313T2 (de) | 1994-02-01 | 2000-07-13 | Ajinomoto Co., Inc. | Verfahren zur Herstellung von Nukleinsäurebasenderivaten |
| US6110923A (en) | 1994-06-22 | 2000-08-29 | Biochem Pharma Inc. | Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity |
| EP0874846B1 (en) | 1995-11-01 | 2003-04-02 | Novartis AG | Purine derivatives and processes for their preparation |
| FR2741881B1 (fr) | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
| US6790958B2 (en) | 1996-08-02 | 2004-09-14 | Robert T. Lum | Purine inhibitors of cyclin dependent kinase 2 & IKBA |
| US5866702A (en) * | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
| AU4920397A (en) | 1996-10-11 | 1998-05-11 | Chiron Corporation | Purine inhibitors of glycogen synthase kinase 3 (gsk3) |
| US6573044B1 (en) | 1997-08-07 | 2003-06-03 | The Regents Of The University Of California | Methods of using chemical libraries to search for new kinase inhibitors |
| US6255485B1 (en) | 1997-08-07 | 2001-07-03 | The Regents Of The University Of California | Purine inhibitors of protein kinases, G proteins and polymerases |
| AU2010399A (en) | 1997-12-24 | 1999-07-19 | Affymetrix, Inc. | Methods of using chemical libraries to search for new kinase inhibitors |
| KR100568658B1 (ko) | 1998-02-26 | 2006-04-07 | 아벤티스 파마슈티칼스 인크 | 6,9-이치환 2-[트랜스-(4-아미노시클로헥실)아미노]퓨린 |
| CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| RU2001124352A (ru) * | 1999-02-01 | 2004-02-20 | Си Ви Терапьютикс, Инк. (Us) | Пуриновые ингибиторы циклин-зависимой киназы 2 и Ikb-альфа |
| US6627633B2 (en) * | 1999-03-17 | 2003-09-30 | Albany Molecular Research, Inc. | 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents |
| IL151946A0 (en) | 2000-03-29 | 2003-04-10 | Cyclacel Ltd | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders |
| GB0107901D0 (en) | 2001-03-29 | 2001-05-23 | Cyclacel Ltd | Anti-cancer compounds |
| JP4381804B2 (ja) * | 2001-06-27 | 2009-12-09 | サイクラセル リミテッド | ２，６，９−置換プリン誘導体及び増殖性疾患の治療におけるその使用 |
| US6812232B2 (en) * | 2001-09-11 | 2004-11-02 | Amr Technology, Inc. | Heterocycle substituted purine derivatives as potent antiproliferative agents |
| US6667311B2 (en) * | 2001-09-11 | 2003-12-23 | Albany Molecular Research, Inc. | Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents |
| NZ531596A (en) | 2001-09-28 | 2005-08-26 | Cyclacel Ltd | N-(4-(4-methylthiazol-5-YL) pyrimidin-2-YL) -N- phenylamine compounds used in the treatment of proliferative disorders such as cancer |
| EP1578722A4 (en) | 2001-10-12 | 2006-09-06 | Irm Llc | KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF |
| US6949644B2 (en) | 2001-10-12 | 2005-09-27 | Irm Llc | Methods for the synthesis of substituted purines |
| EP1465624A1 (en) | 2002-01-10 | 2004-10-13 | Novartis AG | Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof |
| US20030229105A1 (en) * | 2002-05-21 | 2003-12-11 | Cyclacel Limited | Treatment of autoimmune disorders |
| GB0219054D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New purine derivatives |
| GB0219052D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New puring derivatives |
| GB0226583D0 (en) | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| GB0226582D0 (en) | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Anti-viral compounds |
| GB0229581D0 (en) | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
| GB0302220D0 (en) | 2003-01-30 | 2003-03-05 | Cyclacel Ltd | Use |
| GB0315966D0 (en) | 2003-07-08 | 2003-08-13 | Cyclacel Ltd | Compounds |
| JP2007500178A (ja) | 2003-07-30 | 2007-01-11 | サイクラセル・リミテッド | プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体 |
| WO2005012262A1 (en) | 2003-07-30 | 2005-02-10 | Cyclacel Limited | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
| AU2004285745A1 (en) | 2003-10-21 | 2005-05-12 | Cyclacel Limited | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy |
| EP1740587A4 (en) * | 2004-04-02 | 2009-07-15 | Adenosine Therapeutics Llc | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS |
| ES2403558T3 (es) | 2004-08-27 | 2013-05-20 | Cyclacel Limited | Inhibidores purínicos y pirimidínicos de CDK y su uso para el tratamiento de enfermedades autoinmunitarias |
-
2002
- 2002-08-15 GB GBGB0219052.8A patent/GB0219052D0/en not_active Ceased
-
2003
- 2003-08-13 WO PCT/GB2003/003544 patent/WO2004016613A2/en not_active Ceased
- 2003-08-13 DE DE60304871T patent/DE60304871T2/de not_active Expired - Lifetime
- 2003-08-13 AT AT03787886T patent/ATE324374T1/de active
- 2003-08-13 AU AU2003251063A patent/AU2003251063B2/en not_active Ceased
- 2003-08-13 NZ NZ538136A patent/NZ538136A/en not_active IP Right Cessation
- 2003-08-13 CN CNB038194295A patent/CN1312152C/zh not_active Expired - Fee Related
- 2003-08-13 CA CA2488834A patent/CA2488834C/en not_active Expired - Lifetime
- 2003-08-13 BR BRPI0313480-6A patent/BRPI0313480B1/pt unknown
- 2003-08-13 BR BR0313480-6A patent/BR0313480A/pt not_active IP Right Cessation
- 2003-08-13 MX MXPA05001842A patent/MXPA05001842A/es active IP Right Grant
- 2003-08-13 JP JP2004528662A patent/JP4787495B2/ja not_active Expired - Fee Related
- 2003-08-13 EP EP03787886A patent/EP1534708B1/en not_active Expired - Lifetime
- 2003-08-15 GB GB0319258A patent/GB2392156B/en not_active Expired - Fee Related
-
2005
- 2005-02-09 IL IL166783A patent/IL166783A/en active IP Right Grant
- 2005-09-28 US US11/238,533 patent/US7544689B2/en not_active Expired - Fee Related
-
2009
- 2009-04-30 US US12/433,388 patent/US20090270427A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1534708B1 (en) | 2006-04-26 |
| AU2003251063A1 (en) | 2004-03-03 |
| GB0219052D0 (en) | 2002-09-25 |
| JP2006509728A (ja) | 2006-03-23 |
| AU2003251063B2 (en) | 2009-03-26 |
| GB2392156A (en) | 2004-02-25 |
| WO2004016613A3 (en) | 2004-04-08 |
| US20060183760A1 (en) | 2006-08-17 |
| BRPI0313480B1 (pt) | 2017-12-19 |
| EP1534708A2 (en) | 2005-06-01 |
| GB0319258D0 (en) | 2003-09-17 |
| DE60304871T2 (de) | 2006-08-31 |
| CN1312152C (zh) | 2007-04-25 |
| JP4787495B2 (ja) | 2011-10-05 |
| DE60304871D1 (de) | 2006-06-01 |
| ATE324374T1 (de) | 2006-05-15 |
| CA2488834A1 (en) | 2004-02-26 |
| IL166783A0 (en) | 2006-01-15 |
| CA2488834C (en) | 2011-11-01 |
| US7544689B2 (en) | 2009-06-09 |
| CN1675213A (zh) | 2005-09-28 |
| US20090270427A1 (en) | 2009-10-29 |
| GB2392156B (en) | 2005-03-30 |
| NZ538136A (en) | 2007-06-29 |
| MXPA05001842A (es) | 2005-04-19 |
| WO2004016613A2 (en) | 2004-02-26 |
| IL166783A (en) | 2013-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0313477A (pt) | Derivados de purina | |
| BR0313480A (pt) | Derivados de purina | |
| RU2361870C2 (ru) | Новые кумарины, их карбоксамидные производные, способы получения, композиции и применение | |
| AP1753A (en) | Thiophene derivatives as antiviral agents for flavvivirus infection | |
| CY1116119T1 (el) | Παραγωγα ισοξαζολο-πυριδινης | |
| HRP20241540T1 (hr) | Pirolotriazinski spojevi koji djeluju kao inhibitor mnk | |
| MX2009003410A (es) | Fosfoindoles enantiomericamente puros como inhibidores de vih. | |
| ATE440089T1 (de) | Peptid-nukleinsäure-oligomere aus 1-benzol sulfonyl-3-amino säure seitenkette-4-(2-nukleo base(acetyl))piperazin-2-onen | |
| EP1117297A4 (en) | ECTEINASCIDIN-743 SYNTHETIC ANALOGS | |
| SG128491A1 (en) | Heterocyclic sulfonamide inhibitors of beta amyloid production | |
| DE602005023015D1 (de) | Indolderivate als viruzide | |
| BRPI0409465A (pt) | derivados de carboxamida como agentes antidiabéticos | |
| HRP20050390A2 (en) | Substituted benzoxazinones and uses thereof | |
| MY139612A (en) | Benzoxazine derivatives as 5-th6 modulators and uses thereof | |
| RU2010107603A (ru) | Производные n-(2-тиазолил)амида для лечения ожирения, диабетов и сердечно-сосудистых заболеваний | |
| NO930143D0 (no) | Piperidinforbindelser, deres fremstilling og bruk | |
| AR054102A1 (es) | Derivados de fenil-piperazina-metanona. procesos de obtencion y composiciones farmaceuticas | |
| CA2589438C (en) | Treatment of inflammatory bowel disease | |
| TW200716597A (en) | Novel piperidine-substituted indoles | |
| PT1335928E (pt) | Agonistas selectivos do receptor de glucocorticoides | |
| BG105126A (en) | Tetrahydronaphthyridinyl-carboxamides have anti-convulsant activity | |
| JP2003012516A5 (pt) | ||
| WO2004094396A3 (en) | Dihydrothiazine prodrugs of thiazolium agents | |
| ATE513805T1 (de) | Chirale cyclische beta-aminosäuren und ihre derivate, pharmazeutische zusammensetzungen, die diese enthalten, und die verwendung dieser verbindungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: CANCER RESEARCH TECHNOLOGY LIMITED (GB) |
|
| B25K | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication |
Owner name: CANCER RESEARCH TECHNOLOGY LIMITED (GB) , CYCLACEL Free format text: RETIFICACAO DO DESPACHO "(25.1) - TRANSFERENCIA DEFERIDA" PUBLICADO NA RPI NO 2250, DE 18/02/2014, QUANTO AO ITEM "(71) - NOME DO DEPOSITANTE". ONDE SE LE: "(...) DEFIRO A SEGUINTE TRANSFERENCIA DE: CYCLACEL LIMITED; PARA: CANCER RESEARCH TECHNOLOGY LIMITED". LEIA-SE: "(...) DEFIRO A SEGUINTE TRANSFERENCIA PARCIAL DE: CYCLACEL LIMITED; PARA: CANCER RESEARCH TECHNOLOGY LIMITED" |
|
| B25G | Requested change of headquarter approved |
Owner name: CANCER RESEARCH TECHNOLOGY LIMITED (GB) , CYCLACEL |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: CANCER RESEARCH TECHNOLOGY LIMITED (GB) , CYCLACEL |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 16A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2527 DE 11-06-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |